Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trialsMadison Foster, Manoj M. Lalu, Joshua Montroy et al.|Research Involvement and Engagement|2020Cited by 49
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignanciesNatasha Kekre, Brad H. Nelson, Kevin A. Hay et al.|Frontiers in Immunology|2022Cited by 31
Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview studyJustin Presseau, Gisell Castillo, Manoj M. Lalu et al.|Trials|2021Cited by 25
Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trialGisell Castillo, Justin Presseau, Manoj M. Lalu et al.|BMJ Open|2021Cited by 23
Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic ReviewKednapa Thavorn, Natasha Kekre, Emily Rose Thompson et al.|Value in Health|2024Cited by 23